Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Peptic Ulcer

  Free Subscription


Articles published in Helicobacter

Retrieve available abstracts of 156 articles:
HTML format



Single Articles


    October 2021
  1. YANG C, Liang L, Lv P, Liu L, et al
    Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial.
    Helicobacter. 2021 Oct 10:e12856. doi: 10.1111/hel.12856.
    PubMed     Abstract available


  2. BENEJAT L, Ducournau A, Domingues-Martins C, Lecoeur M, et al
    Adaptation of an in-house PCR for the detection of Helicobacter pylori and the mutations associated with macrolide resistance into ready-to-use PCR microwell strips.
    Helicobacter. 2021 Oct 10:e12855. doi: 10.1111/hel.12855.
    PubMed     Abstract available


  3. LAPIDOT Y, Reshef L, Cohen D, Muhsen K, et al
    Helicobacter pylori and the intestinal microbiome among healthy school-age children.
    Helicobacter. 2021 Oct 7:e12854. doi: 10.1111/hel.12854.
    PubMed     Abstract available


    September 2021
  4. VARMA M, Yoe J
    Importance of testing for Helicobacter pylori in patients with immune thrombocytopenia.
    Helicobacter. 2021 Sep 22:e12850. doi: 10.1111/hel.12850.
    PubMed    


  5. LUCERO Y, Lagomarcino AJ, Torres JP, Roessler P, et al
    Effect of Helicobacter pylori eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy school-aged children: A randomized non-blinded trial.
    Helicobacter. 2021 Sep 15:e12853. doi: 10.1111/hel.12853.
    PubMed     Abstract available


  6. ZHAO H, Yan P, Zhang N, Feng L, et al
    The recurrence rate of Helicobacter pylori in recent 10 years: A systematic review and meta-analysis.
    Helicobacter. 2021 Sep 12:e12852. doi: 10.1111/hel.12852.
    PubMed     Abstract available


  7. CHEN HY, Hu Y, Xu XB, Zhou YA, et al
    Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2.
    Helicobacter. 2021 Sep 7:e12849. doi: 10.1111/hel.12849.
    PubMed     Abstract available


  8. SUZUKI S, Gotoda T, Takano C, Horii T, et al
    Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes.
    Helicobacter. 2021 Sep 6:e12851. doi: 10.1111/hel.12851.
    PubMed     Abstract available


    August 2021
  9. YUAN Z, Xiao S, Li S, Suo B, et al
    The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults.
    Helicobacter. 2021 Aug 26:e12848. doi: 10.1111/hel.12848.
    PubMed     Abstract available


  10. YAO X, Xiao S, Zhou L
    Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication.
    Helicobacter. 2021 Aug 20:e12846. doi: 10.1111/hel.12846.
    PubMed     Abstract available


  11. LEE JW, Kim N, Nam RH, Jang JY, et al
    Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance.
    Helicobacter. 2021 Aug 12:e12844. doi: 10.1111/hel.12844.
    PubMed     Abstract available


  12. HSU PI, Tsay FW, Kao JY, Peng NJ, et al
    Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection.
    Helicobacter. 2021 Aug 12:e12840. doi: 10.1111/hel.12840.
    PubMed     Abstract available


  13. GUO R, Wu S, Guan L, Xie Y, et al
    Dietary multivalent anti-Helicobacter pylori immunoglobulin Y significantly increase the H. pylori eradication and improve the clinical symptoms in patients.
    Helicobacter. 2021 Aug 11:e12843. doi: 10.1111/hel.12843.
    PubMed     Abstract available


    July 2021
  14. GONG L, El-Omar EM
    Application of molecular techniques in Helicobacter pylori detection: limitations and improvements.
    Helicobacter. 2021 Jul 31:e12841. doi: 10.1111/hel.12841.
    PubMed    


  15. OUYANG Y, Zhang W, Huang Y, Wang Y, et al
    Effect of Helicobacter pylori eradication on hyperplastic gastric polyps: A systematic review and meta-analysis.
    Helicobacter. 2021 Jul 31:e12838. doi: 10.1111/hel.12838.
    PubMed     Abstract available


  16. LI N, Xu X, Yang H, Wang H, et al
    Activation of Aquaporin 5 by carcinogenic Helicobacter pylori infection promotes epithelial-mesenchymal transition via the MEK/ERK pathway.
    Helicobacter. 2021 Jul 30:e12842. doi: 10.1111/hel.12842.
    PubMed     Abstract available


  17. ZHAO J, Zou Y, Li K, Huang X, et al
    Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis.
    Helicobacter. 2021 Jul 28:e12839. doi: 10.1111/hel.12839.
    PubMed     Abstract available


  18. ZOU PY, Hu J, Zhao JT, Zhao Z, et al
    10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis.
    Helicobacter. 2021 Jul 28:e12833. doi: 10.1111/hel.12833.
    PubMed     Abstract available


  19. KOWADA A, Asaka M
    Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
    Helicobacter. 2021 Jul 18:e12837. doi: 10.1111/hel.12837.
    PubMed     Abstract available


  20. GUNATHILAKE M, Lee J, Choi IJ, Kim YI, et al
    Association between bacteria other than Helicobacter pylori and the risk of gastric cancer.
    Helicobacter. 2021 Jul 15:e12836. doi: 10.1111/hel.12836.
    PubMed     Abstract available


  21. OUYANG Y, Zhu Z, Huang L, Zeng C, et al
    Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 2020.
    Helicobacter. 2021 Jul 13:e12835. doi: 10.1111/hel.12835.
    PubMed     Abstract available


  22. GUNARATNE AW, Hamblin H, Clancy A, Magat AJMC, et al
    Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.
    Helicobacter. 2021 Jul 10:e12830. doi: 10.1111/hel.12830.
    PubMed     Abstract available


  23. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    cagA+ Helicobacter pylori infection and N-nitrosodimethylamine and cholangiocarcinoma.
    Helicobacter. 2021 Jul 8:e12834. doi: 10.1111/hel.12834.
    PubMed    


  24. MA H, Zhao XH, Zhang LL, Wu LM, et al
    Application of WeChat platform in the management of patients infected with Helicobacter pylori.
    Helicobacter. 2021 Jul 7:e12832. doi: 10.1111/hel.12832.
    PubMed     Abstract available


  25. HE Y, Ning J, Li B, Guo H, et al
    IL-9 contributes to the host immune response against Helicobacter pylori and helps limit infection in a Mouse Model.
    Helicobacter. 2021 Jul 7:e12827. doi: 10.1111/hel.12827.
    PubMed     Abstract available


    June 2021
  26. TSAI CF, Chen MH, Wang YP, Liu PY, et al
    Increased risk of short-term depressive disorder after Helicobacter pylori eradication: A population-based nested cohort study.
    Helicobacter. 2021 Jun 11:e12824. doi: 10.1111/hel.12824.
    PubMed     Abstract available


  27. QIU E, Jin S, Xiao Z, Chen Q, et al
    CRISPR-based detection of Helicobacter pylori in stool samples.
    Helicobacter. 2021 Jun 11:e12828. doi: 10.1111/hel.12828.
    PubMed     Abstract available


  28. KOTILEA K, Cadranel S, Salame A, Nguyen J, et al
    Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children.
    Helicobacter. 2021 Jun 7:e12825. doi: 10.1111/hel.12825.
    PubMed     Abstract available


    May 2021
  29. MONZANI A, Lionetti P, Rabbone I, Lionetti E, et al
    The best is the enemy of the good: Time for a biopsy-sparing approach for Helicobacter pylori diagnosis and treatment in children in the COVID-19 era?
    Helicobacter. 2021 May 28:e12826. doi: 10.1111/hel.12826.
    PubMed    


  30. DANGTAKOT R, Intuyod K, Chamgramol Y, Pairojkul C, et al
    CagA(+) Helicobacter pylori infection and N-nitrosodimethylamine administration induce cholangiocarcinoma development in hamsters.
    Helicobacter. 2021 May 24:e12817. doi: 10.1111/hel.12817.
    PubMed     Abstract available


  31. LI C, Shi Y, Suo B, Tian X, et al
    PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis.
    Helicobacter. 2021 May 17:e12816. doi: 10.1111/hel.12816.
    PubMed     Abstract available


  32. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
    Acute gastric mucosal lesions caused by acute infection of non-Helicobacter pylori Helicobacter: a case report.
    Helicobacter. 2021 May 11:e12814. doi: 10.1111/hel.12814.
    PubMed     Abstract available


  33. ZHANG Z, Chen S, Fan M, Ruan G, et al
    Helicobacter pylori induces gastric cancer via down-regulating miR-375 to inhibit dendritic cell maturation.
    Helicobacter. 2021 May 3:e12813. doi: 10.1111/hel.12813.
    PubMed     Abstract available


    April 2021
  34. HERNANDEZ C, Toledo-Stuardo K, Garcia-Gonzalez P, Garrido-Tapia M, et al
    Heat-killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll-like receptor 4.
    Helicobacter. 2021 Apr 29:e12812. doi: 10.1111/hel.12812.
    PubMed     Abstract available


  35. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
    Prevalence, clinical features, and esophagogastroduodenoscopy (EGD) findings of non-Helicobacter pylori Helicobacter infection: A study of 50 cases at a single facility in Japan.
    Helicobacter. 2021 Apr 27:e12811. doi: 10.1111/hel.12811.
    PubMed     Abstract available


  36. WANG X, Shu X, Li Q, Li Y, et al
    Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high-risk area for gastric cancer in northwest China: An all-ages population-based cross-sectional study.
    Helicobacter. 2021 Apr 27:e12810. doi: 10.1111/hel.12810.
    PubMed     Abstract available


  37. ZHOU Y, Ye Z, Wang Y, Huang Z, et al
    Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children.
    Helicobacter. 2021 Apr 25:e12809. doi: 10.1111/hel.12809.
    PubMed     Abstract available


  38. LI SY, Li J, Dong XH, Teng GG, et al
    The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.
    Helicobacter. 2021 Apr 16:e12804. doi: 10.1111/hel.12804.
    PubMed     Abstract available


  39. XIE W, Zhao W, Zou Z, Kong L, et al
    Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice.
    Helicobacter. 2021 Apr 12:e12807. doi: 10.1111/hel.12807.
    PubMed     Abstract available


  40. DO AD, Chang CC, Su CH, Hsu YM, et al
    Lactobacillus rhamnosus JB3 inhibits Helicobacter pylori infection through multiple molecular actions.
    Helicobacter. 2021 Apr 11:e12806. doi: 10.1111/hel.12806.
    PubMed     Abstract available


  41. TURNER KO, Lindberg GM, Genta RM
    Gastric granulomas and Helicobacter pylori: An incidental relationship.
    Helicobacter. 2021 Apr 11:e12805. doi: 10.1111/hel.12805.
    PubMed     Abstract available


  42. YORGUC E, Gulerman HF, Kalkan IH, Guven B, et al
    Comparison of clinical outcomes and FOXP3, IL-17A responses in Helicobacter pylori infection in children versus adults.
    Helicobacter. 2021 Apr 5:e12795. doi: 10.1111/hel.12795.
    PubMed     Abstract available


  43. KUBOTA-AIZAWA S, Matsubara Y, Kanemoto H, Mimuro H, et al
    Transmission of Helicobacter pylori between a human and two dogs: A case report.
    Helicobacter. 2021 Apr 5:e12798. doi: 10.1111/hel.12798.
    PubMed     Abstract available


    March 2021
  44. LI Y, Li X, Tan Z
    An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis.
    Helicobacter. 2021 Mar 25:e12799. doi: 10.1111/hel.12799.
    PubMed     Abstract available


  45. CHIANG TH, Chen CC, Tseng PH, Liou JM, et al
    Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
    Helicobacter. 2021 Mar 19:e12801. doi: 10.1111/hel.12801.
    PubMed     Abstract available


  46. HEFFLEY JD, Zubarik R
    A standardized protocol improves testing rates for Helicobacter Pylori among inpatients with peptic ulcer disease.
    Helicobacter. 2021 Mar 15:e12800. doi: 10.1111/hel.12800.
    PubMed     Abstract available


  47. MARUBASHI K, Takakusagi S, Yokoyama Y, Kizawa K, et al
    Changes of (18) F-fluoro-2-deoxyglucose position-emission tomography findings by the eradication of Helicobacter pylori in the stomach.
    Helicobacter. 2021 Mar 8:e12797. doi: 10.1111/hel.12797.
    PubMed     Abstract available


  48. ZHAO JB, Yuan L, Yu XC, Shao QQ, et al
    Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis.
    Helicobacter. 2021 Mar 6:e12793. doi: 10.1111/hel.12793.
    PubMed     Abstract available


  49. JAIN U, Saxena K, Chauhan N
    Helicobacter pylori induced reactive oxygen Species: A new and developing platform for detection.
    Helicobacter. 2021 Mar 5:e12796. doi: 10.1111/hel.12796.
    PubMed     Abstract available


  50. TENG TZJ, Sudharsan M, Yau JWK, Tan W, et al
    Helicobacter pylori knowledge and perception among multi-ethnic Asians.
    Helicobacter. 2021 Mar 3:e12794. doi: 10.1111/hel.12794.
    PubMed     Abstract available


  51. KIM YJ, Chung WC, Kim DB
    Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
    Helicobacter. 2021 Mar 1:e12792. doi: 10.1111/hel.12792.
    PubMed     Abstract available


    February 2021
  52. HUANG Y, Ding Y, Xu H, Shen C, et al
    Effects of sodium butyrate supplementation on inflammation, gut microbiota, and short-chain fatty acids in Helicobacter pylori-infected mice.
    Helicobacter. 2021 Feb 20:e12785. doi: 10.1111/hel.12785.
    PubMed     Abstract available


  53. XIE M, Li Q, Zhang B, Zhang Q, et al
    Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients.
    Helicobacter. 2021 Feb 18:e12791. doi: 10.1111/hel.12791.
    PubMed     Abstract available


  54. GANTUYA B, El Serag HB, Saruuljavkhlan B, Azzaya D, et al
    Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis.
    Helicobacter. 2021 Feb 17:e12790. doi: 10.1111/hel.12790.
    PubMed     Abstract available


  55. LEE BE, Kim JS, Kim BW, Kim JH, et al
    Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years.
    Helicobacter. 2021 Feb 17:e12780. doi: 10.1111/hel.12780.
    PubMed     Abstract available


  56. WU ZF, Zou K, Xiang CJ, Jin ZJ, et al
    Helicobacter pylori infection is associated with the co-occurrence of bacteria in the oral cavity and the gastric mucosa.
    Helicobacter. 2021 Feb 17:e12786. doi: 10.1111/hel.12786.
    PubMed     Abstract available


  57. YANG KY, Kao CY, Su MS, Wang S, et al
    Glycosyltransferase Jhp0106 (PseE) contributes to flagellin maturation in Helicobacter pylori.
    Helicobacter. 2021 Feb 15:e12787. doi: 10.1111/hel.12787.
    PubMed     Abstract available


  58. LACOUT C, Savey L, Bourguiba R, Giurgea I, et al
    "Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france".
    Helicobacter. 2021 Feb 15:e12789. doi: 10.1111/hel.12789.
    PubMed     Abstract available


  59. ETO H, Suzuki S, Kusano C, Ikehara H, et al
    Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
    Helicobacter. 2021 Feb 12:e12788. doi: 10.1111/hel.12788.
    PubMed     Abstract available


  60. HU Y, Ouyang Y, Zhu Y, Lu NH, et al
    Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Helicobacter. 2021 Feb 3:e12784. doi: 10.1111/hel.12784.
    PubMed     Abstract available


    January 2021
  61. PARK Y, Kim TJ, Lee H, Yoo H, et al
    Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study.
    Helicobacter. 2021 Jan 28:e12783. doi: 10.1111/hel.12783.
    PubMed     Abstract available


  62. DOMANOVICH-ASOR T, Craddock HA, Motro Y, Khalfin B, et al
    Unraveling antimicrobial resistance in Helicobacter pylori: Global resistome meets global phylogeny.
    Helicobacter. 2021 Jan 25:e12782. doi: 10.1111/hel.12782.
    PubMed     Abstract available


  63. SONG X, Cai C, Jin Q, Chen X, et al
    The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis.
    Helicobacter. 2021 Jan 19:e12781. doi: 10.1111/hel.12781.
    PubMed     Abstract available


  64. WEN Y, Huang H, Tang T, Yang H, et al
    AI-2 represses CagA expression and bacterial adhesion, attenuating the Helicobacter pylori-induced inflammatory response of gastric epithelial cells.
    Helicobacter. 2021 Jan 5:e12778. doi: 10.1111/hel.12778.
    PubMed     Abstract available


  65. MUNOZ AB, Trespalacios-Rangel AA, Vale FF
    An American lineage of Helicobacter pylori prophages found in Colombia.
    Helicobacter. 2021 Jan 5:e12779. doi: 10.1111/hel.12779.
    PubMed     Abstract available


  66. JUNG K, Kim DH, Seo HI, Gong EJ, et al
    Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis.
    Helicobacter. 2021 Jan 5:e12774. doi: 10.1111/hel.12774.
    PubMed     Abstract available


    December 2020
  67. XUE Q, Li X, Li Y, Xu J, et al
    Dialogue between gastrointestinal tract and skin: New insights into the Helicobacter pylori and atopic dermatitis.
    Helicobacter. 2020 Dec 23:e12771. doi: 10.1111/hel.12771.
    PubMed     Abstract available


  68. QARIA MA, Qumar S, Sepe LP, Ahmed N, et al
    Cholesterol glucosylation-based survival strategy in Helicobacter pylori.
    Helicobacter. 2020 Dec 23:e12777. doi: 10.1111/hel.12777.
    PubMed     Abstract available


  69. KAKIUCHI T, Matsuo M, Endo H, Sakata Y, et al
    Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study.
    Helicobacter. 2020 Dec 23:e12776. doi: 10.1111/hel.12776.
    PubMed     Abstract available


  70. JUKIC I, Vukovic J, Rusic D, Bozic J, et al
    Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study.
    Helicobacter. 2020 Dec 23:e12775. doi: 10.1111/hel.12775.
    PubMed     Abstract available


  71. BANGA NDZOUBOUKOU JL, Lei Q, Ullah N, Zhang Y, et al
    Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori.
    Helicobacter. 2020 Dec 1:e12758. doi: 10.1111/hel.12758.
    PubMed     Abstract available


    November 2020
  72. CEN Q, Gao T, Ren Y, Lu X, et al
    Immune evaluation of a Saccharomyces cerevisiae-based oral vaccine against Helicobacter pylori in mice.
    Helicobacter. 2020 Nov 20:e12772. doi: 10.1111/hel.12772.
    PubMed     Abstract available


  73. GRAHAM DY, Megraud F
    Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy.
    Helicobacter. 2020 Nov 18:e12773. doi: 10.1111/hel.12773.
    PubMed    


  74. SINGH H, Chung H, Awan I, Mone A, et al
    Designing strategies for eradication of Helicobacter pylori based on prevalence patterns of infection and antibiotic resistance in a low-income, medically underserved community in the United States.
    Helicobacter. 2020 Nov 9:e12769. doi: 10.1111/hel.12769.
    PubMed     Abstract available


    October 2020
  75. PIH GY, Choi KD, Gong EJ, Na HK, et al
    Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
    Helicobacter. 2020 Oct 28:e12759. doi: 10.1111/hel.12759.
    PubMed     Abstract available


  76. MEGRAUD F, Alix C, Charron P, Benejat L, et al
    Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years.
    Helicobacter. 2020 Oct 22:e12767. doi: 10.1111/hel.12767.
    PubMed     Abstract available


  77. KE H, Li J, Lu B, Yang C, et al
    The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.
    Helicobacter. 2020 Oct 21:e12768. doi: 10.1111/hel.12768.
    PubMed     Abstract available


  78. QUMAR S, Nguyen TH, Nahar S, Sarker N, et al
    A comparative whole genome analysis of Helicobacter pylori from a human dense South Asian setting.
    Helicobacter. 2020 Oct 18:e12766. doi: 10.1111/hel.12766.
    PubMed     Abstract available


  79. MIYATA E, Kudo T, Ikuse T, Tokita K, et al
    Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single-center study over 12 years.
    Helicobacter. 2020 Oct 18:e12764. doi: 10.1111/hel.12764.
    PubMed     Abstract available


  80. HOFREUTER D, Behrendt J, Franz A, Meyer J, et al
    Antimicrobial resistance of Helicobacter pylori in an eastern German region.
    Helicobacter. 2020 Oct 17:e12765. doi: 10.1111/hel.12765.
    PubMed     Abstract available


  81. SONG Z, Zhou L, Xue Y, Suo B, et al
    A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
    Helicobacter. 2020 Oct 11:e12762. doi: 10.1111/hel.12762.
    PubMed     Abstract available


  82. WANG B, Yu M, Zhang R, Chen S, et al
    A meta-analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease.
    Helicobacter. 2020 Oct 7:e12761. doi: 10.1111/hel.12761.
    PubMed     Abstract available


  83. ALVAREZ CS, Florio AA, Butt J, Rivera-Andrade A, et al
    Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala.
    Helicobacter. 2020 Oct 2:e12756. doi: 10.1111/hel.12756.
    PubMed     Abstract available


  84. HUANG JW, Xie C, Niu Z, He LJ, et al
    The relation between Helicobacter pylori immunoglobulin G seropositivity and leukocyte telomere length in US adults from NHANES 1999-2000.
    Helicobacter. 2020 Oct 1:e12760. doi: 10.1111/hel.12760.
    PubMed     Abstract available


    September 2020
  85. ARSLAN M, Balamtekin N, Gunal A
    Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children.
    Helicobacter. 2020 Sep 17:e12757. doi: 10.1111/hel.12757.
    PubMed     Abstract available


  86. ZHOU JJ, Shi X, Zheng SP, Tang D, et al
    Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China.
    Helicobacter. 2020 Sep 11:e12755. doi: 10.1111/hel.12755.
    PubMed     Abstract available


  87. SUAREZ-JARAMILLO A, Baldeon ME, Prado B, Fornasini M, et al
    Duodenal microbiome in patients with or without Helicobacter pylori infection.
    Helicobacter. 2020 Sep 8:e12753. doi: 10.1111/hel.12753.
    PubMed     Abstract available


  88. TAO ZH, Han JX, Fang JY
    Helicobacter pylori infection and eradication: Exploring their impacts on the gastrointestinal microbiota.
    Helicobacter. 2020 Sep 2:e12754. doi: 10.1111/hel.12754.
    PubMed     Abstract available


  89. GODBOLE G, Megraud F, Bessede E
    Review: Diagnosis of Helicobacter pylori infection.
    Helicobacter. 2020;25 Suppl 1:e12735.
    PubMed     Abstract available


  90. SEO JH, Bortolin K, Jones NL
    Review: Helicobacter pylori infection in children.
    Helicobacter. 2020;25 Suppl 1:e12742.
    PubMed     Abstract available


  91. DENIC M, Touati E, De Reuse H
    Review: Pathogenesis of Helicobacter pylori infection.
    Helicobacter. 2020;25 Suppl 1:e12736.
    PubMed     Abstract available


  92. O'CONNOR A, Furuta T, Gisbert JP, O'Morain C, et al
    Review - Treatment of Helicobacter pylori infection 2020.
    Helicobacter. 2020;25 Suppl 1:e12743.
    PubMed     Abstract available


  93. SCHULZ C, Kupcinskas J
    Review - Helicobacter pylori and non-malignant upper gastro-intestinal diseases.
    Helicobacter. 2020;25 Suppl 1:e12738.
    PubMed     Abstract available


  94. MEZMALE L, Coelho LG, Bordin D, Leja M, et al
    Review: Epidemiology of Helicobacter pylori.
    Helicobacter. 2020;25 Suppl 1:e12734.
    PubMed     Abstract available


  95. PELLICANO R, Ianiro G, Fagoonee S, Settanni CR, et al
    Review: Extragastric diseases and Helicobacter pylori.
    Helicobacter. 2020;25 Suppl 1:e12741.
    PubMed     Abstract available


    August 2020
  96. YUSIBOVA M, Hasman H, Clausen PTLC, Imkamp F, et al
    CRHP Finder, a webtool for the detection of clarithromycin resistance in Helicobacter pylori from whole-genome sequencing data.
    Helicobacter. 2020 Aug 26:e12752. doi: 10.1111/hel.12752.
    PubMed     Abstract available


  97. ESLICK GD, Tilden D, Arora N, Torres M, et al
    Clinical and economic impact of "triple therapy" for Helicobacter pylori eradication on peptic ulcer disease in Australia.
    Helicobacter. 2020 Aug 20:e12751. doi: 10.1111/hel.12751.
    PubMed     Abstract available


  98. SALEHI N, Attaran B, Zare-Mirakabad F, Ghadiri B, et al
    The outward shift of clarithromycin binding to the ribosome in mutant Helicobacter pylori strains.
    Helicobacter. 2020 Aug 14:e12731. doi: 10.1111/hel.12731.
    PubMed     Abstract available


  99. NAKAMURA M, Overby A, Michimae H, Matsui H, et al
    PCR analysis and specific immunohistochemistry revealing a high prevalence of non-Helicobacter pylori Helicobacters in Helicobacter pylori-negative gastric disease patients in Japan: High susceptibility to an Hp eradication regimen.
    Helicobacter. 2020 Aug 13:e12700. doi: 10.1111/hel.12700.
    PubMed     Abstract available


  100. GUDRA D, Pupola D, Skenders G, Leja M, et al
    Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 years after a single eradication event.
    Helicobacter. 2020 Aug 9:e12748. doi: 10.1111/hel.12748.
    PubMed     Abstract available


  101. ZHANG Y, Dong Q, Tian L, Zhang S, et al
    Risk factors for recurrence of Helicobacter pylori infection after successful eradication in Chinese children: A prospective, nested case-control study.
    Helicobacter. 2020 Aug 7:e12749. doi: 10.1111/hel.12749.
    PubMed     Abstract available


  102. GONG EJ, Ahn JY, Jung DK, Lee SM, et al
    Isolation of Helicobacter pylori using leftover tissue in the rapid urease test kit.
    Helicobacter. 2020 Aug 3:e12733. doi: 10.1111/hel.12733.
    PubMed     Abstract available


    July 2020
  103. KAWAHARA Y, Hirashita Y, Tamura C, Kudo Y, et al
    Helicobacter pylori infection modulates endogenous hydrogen sulfide production in gastric cancer AGS cells.
    Helicobacter. 2020 Jul 26:e12732. doi: 10.1111/hel.12732.
    PubMed     Abstract available


  104. HWONG-RUEY LEOW A, Chang JV, Goh KL
    Searching for an optimal therapy for H pylori eradication: High-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days.
    Helicobacter. 2020 Jul 26:e12723. doi: 10.1111/hel.12723.
    PubMed     Abstract available


  105. SHOLEH M, Maleki F, Krutova M, Bavari S, et al
    The increasing antimicrobial resistance of Helicobacter pylori in Iran: A systematic review and meta-analysis.
    Helicobacter. 2020 Jul 23:e12730. doi: 10.1111/hel.12730.
    PubMed     Abstract available


  106. KHIDDI F, Abdellahi MVM, Horma MA, Billoet A, et al
    Characteristics of Helicobacter pylori strains isolated from Mauritanian patients.
    Helicobacter. 2020 Jul 19:e12726. doi: 10.1111/hel.12726.
    PubMed     Abstract available


  107. PUNDAK OY, Topf Olivestone C, Hofi L, Kori M, et al
    Lack of association between Helicobacter pylori infection and childhood overweight/obesity.
    Helicobacter. 2020 Jul 19:e12728. doi: 10.1111/hel.12728.
    PubMed     Abstract available


  108. LI M, Sun Y, Yang J, de Martel C, et al
    Time trends and other sources of variation in Helicobacter pylori infection in mainland China: A systematic review and meta-analysis.
    Helicobacter. 2020 Jul 19:e12729. doi: 10.1111/hel.12729.
    PubMed     Abstract available


  109. WINDHAM IH, Merrell DS
    Analysis of fitness costs associated with metronidazole and amoxicillin resistance in Helicobacter pylori.
    Helicobacter. 2020 Jul 16:e12724. doi: 10.1111/hel.12724.
    PubMed     Abstract available


  110. PAL S, Sarker N, Qaria M, Tandon K, et al
    Design of an inhibitor of Helicobacter pylori cholesteryl-alpha-glucoside transferase critical for bacterial colonization.
    Helicobacter. 2020 Jul 15:e12720. doi: 10.1111/hel.12720.
    PubMed     Abstract available


  111. HEYDARI S, Siavoshi F, Jazayeri MH, Sarrafnejad A, et al
    Helicobacter pylori release from yeast as a vesicle-encased or free bacterium.
    Helicobacter. 2020 Jul 14:e12725. doi: 10.1111/hel.12725.
    PubMed     Abstract available


  112. NYSSEN OP, Perez-Aisa A, Rodrigo L, Castro M, et al
    Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
    Helicobacter. 2020 Jul 13:e12722. doi: 10.1111/hel.12722.
    PubMed     Abstract available


    June 2020
  113. HIRATA Y, Yamada A, Niikura R, Shichijo S, et al
    Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
    Helicobacter. 2020 Jun 29:e12719. doi: 10.1111/hel.12719.
    PubMed     Abstract available


  114. DEMIR AM, Berberoglu Ates B, Hizal G, Yaman A, et al
    Autoimmune atrophic gastritis: The role of Helicobacter pylori infection in children.
    Helicobacter. 2020 Jun 26:e12716. doi: 10.1111/hel.12716.
    PubMed     Abstract available


  115. GOKISIK MT, Uyar S
    The role of Helicobacter pylori in vitamin-B12 deficiency due to metformin use.
    Helicobacter. 2020 Jun 19:e12718. doi: 10.1111/hel.12718.
    PubMed     Abstract available


  116. CAI Y, Wang C, Chen Z, Xu Z, et al
    Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in Helicobacter pylori by enhancing drug efflux.
    Helicobacter. 2020 Jun 16:e12715. doi: 10.1111/hel.12715.
    PubMed     Abstract available


  117. ZOU Y, Qian X, Liu X, Song Y, et al
    The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis.
    Helicobacter. 2020 Jun 12:e12714. doi: 10.1111/hel.12714.
    PubMed     Abstract available


  118. YE Q, Shao X, Shen R, Chen D, et al
    Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis.
    Helicobacter. 2020 Jun 9:e12713. doi: 10.1111/hel.12713.
    PubMed     Abstract available


    May 2020
  119. WU Y, Su T, Zhou X, Lu N, et al
    Awareness and attitudes regarding Helicobacter pylori infection in Chinese physicians and public population: A national cross-sectional survey.
    Helicobacter. 2020 May 31:e12705. doi: 10.1111/hel.12705.
    PubMed     Abstract available


  120. JAIN U, Gupta S, Soni S, Khurana MP, et al
    Triple-nanostructuring-based noninvasive electro-immune sensing of CagA toxin for Helicobacter pylori detection.
    Helicobacter. 2020 May 29:e12706. doi: 10.1111/hel.12706.
    PubMed     Abstract available


  121. SEO KI, Heo JJ, Kim SE, Park SJ, et al
    Sex differences between Helicobacter pylori infection and cholesterol levels in an adult health checkup program.
    Helicobacter. 2020 May 26:e12704. doi: 10.1111/hel.12704.
    PubMed     Abstract available


  122. TANG X, Shen Y, Hu R, Yang T, et al
    Re-assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori.
    Helicobacter. 2020 May 26:e12703. doi: 10.1111/hel.12703.
    PubMed     Abstract available


  123. LUO L, Huang Y, Liang X, Ji Y, et al
    Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies.
    Helicobacter. 2020 May 19:e12699. doi: 10.1111/hel.12699.
    PubMed     Abstract available


  124. JEHANNE Q, Benejat L, Megraud F, Bessede E, et al
    Evaluation of the Allplex H pylori and ClariR PCR Assay for Helicobacter pylori detection on gastric biopsies.
    Helicobacter. 2020 May 19:e12702. doi: 10.1111/hel.12702.
    PubMed     Abstract available


  125. ZHANG J, Chen Y, Chen W, Xu H, et al
    Persistent infection of Helicobacter pylori affects weight loss in obese population compared with persistent negative: A case-control study based on healthy Chinese.
    Helicobacter. 2020 May 15:e12697. doi: 10.1111/hel.12697.
    PubMed     Abstract available


  126. MIFTAHUSSURUR M, Waskito LA, El-Serag HB, Ajami NJ, et al
    Gastric microbiota and Helicobacter pylori in Indonesian population.
    Helicobacter. 2020 May 12:e12695. doi: 10.1111/hel.12695.
    PubMed     Abstract available


  127. HORIE R, Handa O, Ando T, Ose T, et al
    Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
    Helicobacter. 2020 May 5:e12698. doi: 10.1111/hel.12698.
    PubMed     Abstract available


    April 2020
  128. KAJI E, Yoden A, Otani M, Okuhira T, et al
    Helicobacter pylori test-and-treat strategy for second-year junior high school students aimed at the prevention of gastric cancer in Takatsuki City.
    Helicobacter. 2020 Apr 30:e12696. doi: 10.1111/hel.12696.
    PubMed     Abstract available


  129. GAO CP, Zhang D, Zhang T, Wang JX, et al
    PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis.
    Helicobacter. 2020 Apr 20:e12692. doi: 10.1111/hel.12692.
    PubMed     Abstract available


  130. BERESNIAK A, Malfertheiner P, Franceschi F, Liebaert F, et al
    Helicobacter pylori "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative.
    Helicobacter. 2020 Apr 13:e12693. doi: 10.1111/hel.12693.
    PubMed     Abstract available


  131. BAYRAK NA, Tutar E, Volkan B, Sahin Akkelle B, et al
    Helicobacter pylori infection in children with celiac disease: Multi-center, cross-sectional study.
    Helicobacter. 2020 Apr 1:e12691. doi: 10.1111/hel.12691.
    PubMed     Abstract available


    March 2020
  132. KAKIUCHI T, Mizoe A, Yamamoto K, Imamura I, et al
    Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial.
    Helicobacter. 2020 Mar 24:e12690. doi: 10.1111/hel.12690.
    PubMed     Abstract available


  133. DOORAKKERS E, Lagergren J, Santoni G, Engstrand L, et al
    Helicobacter pylori eradication treatment and the risk of Barrett's esophagus and esophageal adenocarcinoma.
    Helicobacter. 2020 Mar 16:e12688. doi: 10.1111/hel.12688.
    PubMed     Abstract available


  134. NYSSEN OP, Perez-Aisa A, Tepes B, Rodrigo-Saez L, et al
    Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).
    Helicobacter. 2020 Mar 16:e12686. doi: 10.1111/hel.12686.
    PubMed     Abstract available


  135. ALBERTS CJ, Jeske R, de Martel C, den Hollander WJ, et al
    Helicobacter pylori seroprevalence in six different ethnic groups living in Amsterdam: The HELIUS study.
    Helicobacter. 2020 Mar 9:e12687. doi: 10.1111/hel.12687.
    PubMed     Abstract available


  136. YOON K, Kim N, Lee JW, Yoon H, et al
    Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
    Helicobacter. 2020 Mar 6:e12685. doi: 10.1111/hel.12685.
    PubMed     Abstract available


    February 2020
  137. ARSHAD U, Sarkar S, Alipour Talesh G, Sutton P, et al
    A lack of role for antibodies in regulating Helicobacter pylori colonization and associated gastritis.
    Helicobacter. 2020 Feb 23:e12681. doi: 10.1111/hel.12681.
    PubMed     Abstract available


  138. LUO M, Hao Y, Tang M, Shi M, et al
    Application of a social media platform as a patient reminder in the treatment of Helicobacter pylori.
    Helicobacter. 2020 Feb 23:e12682. doi: 10.1111/hel.12682.
    PubMed     Abstract available


  139. HAMIDI S, Badmasti F, Sadeghpour Heravi F, Safapoor MH, et al
    Antibiotic resistance and clonal relatedness of Helicobacter pylori strains isolated from stomach biopsy specimens in northeast of Iran.
    Helicobacter. 2020 Feb 19:e12684. doi: 10.1111/hel.12684.
    PubMed     Abstract available


  140. KIM JY, Lee SY, Kim JH, Sung IK, et al
    Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication.
    Helicobacter. 2020 Feb 19:e12683. doi: 10.1111/hel.12683.
    PubMed     Abstract available


  141. SELIGOVA B, Lukac L, Babelova M, Vavrova S, et al
    Diagnostic reliability of nested PCR depends on the primer design and threshold abundance of Helicobacter pylori in biopsy, stool, and saliva samples.
    Helicobacter. 2020 Feb 14:e12680. doi: 10.1111/hel.12680.
    PubMed     Abstract available


    January 2020
  142. ZHOU Y, Ye Z, Wang Y, Zhang Y, et al
    Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
    Helicobacter. 2020 Jan 20:e12679. doi: 10.1111/hel.12679.
    PubMed     Abstract available


    December 2019
  143. KADKHODAEI S, Siavoshi F, Akbari Noghabi K
    Mucoid and coccoid Helicobacter pylori with fast growth and antibiotic resistance.
    Helicobacter. 2019 Dec 26:e12678. doi: 10.1111/hel.12678.
    PubMed     Abstract available


  144. SHAMSDIN SA, Alborzi A, Ghaderi A, Lankrani KB, et al
    Significance of TC9 and TH9 in Helicobacter pylori-induced gastritis.
    Helicobacter. 2019 Dec 5:e12672. doi: 10.1111/hel.12672.
    PubMed     Abstract available


    November 2019
  145. MIAO R, Wan C, Wang Z
    The relationship of gastric microbiota and Helicobacter pylori infection in pediatrics population.
    Helicobacter. 2019 Nov 24:e12676. doi: 10.1111/hel.12676.
    PubMed     Abstract available


  146. BUTT J, Blot WJ, Shrubsole MJ, Varga MG, et al
    Performance of multiplex serology in discriminating active vs past Helicobacter pylori infection in a primarily African American population in the southeastern United States.
    Helicobacter. 2019 Nov 20:e12671. doi: 10.1111/hel.12671.
    PubMed     Abstract available


  147. MUHSEN K, Na'amnih W, Adler A, Carmeli Y, et al
    Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study.
    Helicobacter. 2019 Nov 13:e12668. doi: 10.1111/hel.12668.
    PubMed     Abstract available


  148. ROCHA GA, de Melo FF, Cabral MMDA, de Brito BB, et al
    Interleukin-27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori-associated gastroduodenal diseases.
    Helicobacter. 2019 Nov 8:e12667. doi: 10.1111/hel.12667.
    PubMed     Abstract available


  149. KOCSMAR E, Kocsmar I, Buzas GM, Szirtes I, et al
    Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept.
    Helicobacter. 2019 Nov 8:e12670. doi: 10.1111/hel.12670.
    PubMed     Abstract available


  150. PAPAEFTHYMIOU A, Liatsos C, Georgopoulos SD, Apostolopoulos P, et al
    Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.
    Helicobacter. 2019 Nov 6:e12666. doi: 10.1111/hel.12666.
    PubMed     Abstract available


  151. KISHIKAWA H, Ojiro K, Nakamura K, Katayama T, et al
    Previous Helicobacter pylori infection-induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication.
    Helicobacter. 2019 Nov 3:e12669. doi: 10.1111/hel.12669.
    PubMed     Abstract available


    October 2019
  152. PONZETTO A, Figura N
    Prevalence of ischemic stroke and Helicobacter pylori infection.
    Helicobacter. 2019 Oct 27:e12664. doi: 10.1111/hel.12664.
    PubMed    


  153. GUO Y, Zhang T, Shi Y, Zhang J, et al
    Helicobacter pylori inhibits GKN1 expression via the CagA/p-ERK/AUF1 pathway.
    Helicobacter. 2019 Oct 27:e12665. doi: 10.1111/hel.12665.
    PubMed     Abstract available


  154. YU Y, Yao X, Liang J, Lu C, et al
    Is Helicobacter pylori associated with Behcet's syndrome? A meta-analysis.
    Helicobacter. 2019 Oct 16:e12663. doi: 10.1111/hel.12663.
    PubMed     Abstract available


  155. SONG C, Xie C, Zhu Y, Liu W, et al
    Management of Helicobacter pylori infection by clinicians: A nationwide survey in a developing country.
    Helicobacter. 2019 Oct 1:e12656. doi: 10.1111/hel.12656.
    PubMed     Abstract available


    September 2019
  156. DE SENA-REIS JS, Bezerra DD, Figueiredo CA, Barreto ML, et al
    Relationship between African Biogeographical Ancestry and Helicobacter pylori infection in children of a large Latin American urban center.
    Helicobacter. 2019 Sep 30:e12662. doi: 10.1111/hel.12662.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Peptic Ulcer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: